Bladder cancer company Photocure ASA (OSE:PHO) on Friday announced the publication of the BRAVO study in JU Open Plus, demonstrating the clinical benefits of blue light cystoscopy (BLC) in non-muscle invasive bladder cancer (NMIBC).

The study, conducted within the Veterans Affairs Healthcare System, compared oncologic outcomes of BLC-assisted transurethral resection of bladder tumors (TURBT) to white light cystoscopy (WLC) alone.

Results showed a 38% reduction in recurrence risk for BLC patients over a three-year period. A positive trend toward lower progression risk was also observed, though not statistically significant. The study included 626 patients, with a median age of 71 and a median follow-up of 3.7 years.

BLC patients were significantly more likely to receive intravesical BCG therapy (61% vs. 43%) or intravesical chemotherapy (48% vs. 27%). Findings suggest that BLC improves risk stratification, leading to more precise treatment decisions and better patient outcomes.